IP Library Granted Patent US 8,901,133
Granted Patent B2
US 8,901,133 · App. 13/293,828 · Granted Dec 2, 2014

Heterocyclic compounds and uses thereof

Inventors: Pingda Ren (San Diego, CA); Yi Liu (San Diego, CA); Liansheng Li (San Diego, CA); Katrina Chan (San Diego, CA); Troy Edward Wilson (San Marino, CA); Alfredo C. Castro (Winchester, MA); Catherine A. Evans (Somerville, MA); Daniel A. Snyder (Somerville, MA)
Assignee: Infinity Pharmaceuticals, Inc.
C07D473/34C07D519/00C07D401/12C07D471/04C07D487/04C07D513/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,901,133
App. No.
13/293,828
Granted
Dec 2, 2014
Kind
B2
Abstract

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Claims (95)

1. A compound of Formula (Ia):

or a pharmaceutically acceptable form thereof, wherein:

W 5 is CR 4 ;

R 4 is hydrogen, alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, thio, sulfoxide, sulfone, halo, cyano, hydroxy, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety;

Cy is aryl substituted by 0-4 occurrences of R 3 ;

R 1 is -(L) n -R 1′ ;

each L is independently a bond, alkylene, heteroalkylene, —N(R 2 )—, —S(═O)—, —S(═O) 2 —, —S—, —C(═O)—, —P(═O)R 2 —, or —O—;

R 1′ is hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocyclyloxy, heterocycloalkyloxy, amino, amido, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, nitro, phosphate, urea, carbonate, —(C═O)—NR a1 R a2 , or NR a1 R a2 ;

R a1 and R a2 are each independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, thio, sulfoxide, sulfone, halo, cyano, hydroxy, nitro, phosphate, urea, carbonate, or R a1 and R a2 are taken together with nitrogen to form a cyclic moiety;

R 2 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroalkyl, aryl, or heteroaryl;

each R 3 is independently alkyl, heteroalkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, thio, sulfoxide, sulfone, halo, cyano, hydroxy, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety;

X is —(CH(R 10 )) z —;

Y is absent, —O—, —S—, —S(═O)—, —S(═O) 2 —, —N(R 9 )—, —C(═O)—(CHR 10 ) z —, —C(═O)—, —N(R 9 )—C(═O)—, —C(═O)—N(R 9 )—, —N(R 9 )—C(═O)NH—, —N(R 9 )C(R 10 ) 2 —, —C(═O)—N(R 9 )—(CHR 10 ) z —, or —P(═O)R 2 —;

each z is an integer of 1, 2, 3, or 4;

n is an integer of 0, 1, 2, 3, or 4;

each R 9 is independently hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroalkyl, aryl, or heteroaryl;

W d is

each R b is independently hydrogen, halo, phosphate, urea, carbonate, alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, or heterocycloalkyl; and

each R 10 , R 11 , and R 12 is independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocyclyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, haloalkyl, cyano, hydroxyl, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety.

2. The compound of claim 1 , wherein n is 1, 2, or 3.

3. The compound of claim 1 , wherein each L is —O—, —C(═O)—, —S(═O)—, —S(═O) 2 —, —S—, alkylene, or a bond.

4. The compound of claim 1 , wherein R 1′ is alkyl, hydroxy, aryl, heteroaryl, aralkyl, —(C═O)—NR a1 R a2 , or NR a1 R a2 .

5. The compound of claim 4 , wherein R a1 is hydrogen or alkyl.

6. The compound of claim 4 , wherein R a2 is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, acyl, or heterocycloalkylalkyl.

7. The compound of claim 4 , wherein R a1 and R a2 are taken together with the nitrogen to which they are attached to form a cyclic moiety.

8. The compound of claim 1 , wherein W 5 is CH.

9. The compound of claim 1 , wherein X is —(CH(R 10 )) z — and z is 1 or 2.

10. The compound of claim 1 , wherein Y is absent, —O—, —NH(R 9 )—, or —S(═O) 2 —.

11. The compound of claim 1 , wherein Cy is phenyl substituted with 0-4 occurrences of R 3 .

12. The compound of claim 1 , wherein Cy is phenyl substituted with 1 occurrence of R 3 .

13. The compound of claim 1 , wherein R 3 is halo, alkyl, haloalkyl, acyl, or heteroaryl.

14. The compound of claim 1 , wherein R 10 is hydrogen.

15. The compound of claim 1 , wherein R 12 is hydrogen, halo, haloalkyl, cyano, amino, or amido.

16. The compound of claim 1 , wherein the compound of Formula (Ia) is a compound of Formula (II):

or a pharmaceutically acceptable form thereof, wherein:

W 1 is CR 14 , W 2 is CR 6 , W 3 is CR 7 , and W 4 is CR 8 ; and

R 6 , R 7 , R 8 and R 14 are independently hydrogen, alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, thio, sulfoxide, sulfone, halo, cyano, hydroxy, nitro, phosphate, urea, carbonate, or NR′R″, wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety.

17. The compound of claim 16 , wherein R 1′ is hydrogen, amino, alkoxy, alkyl, heterocycloalkyl, aryl, or NR a1 R a2 , wherein R a1 and R a2 are taken together with nitrogen to form a cyclic moiety.

18. The compound of claim 16 , wherein R 1′ is amino, alkoxy, alkyl, or NR a1 R a2 , wherein R a1 and R a2 are taken together with nitrogen to form a cyclic moiety.

19. The compound of claim 1 , wherein the compound of Formula (Ia) is a compound of Formula (IIIa):

or a pharmaceutically acceptable form thereof, wherein:

W 1 is CR 14 , W 2 is CR 6 , W 3 is CR 7 , and W 4 is CR 8 ; and

R 6 , R 7 , R 8 and R 14 are independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, thio, sulfoxide, sulfone, halo, cyano, hydroxy, nitro, phosphate, urea, carbonate, or NR′R″, wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety.

20. The compound of claim 19 , wherein R a1 and R a2 are taken together with nitrogen to form a cyclic moiety.

21. The compound of claim 20 , wherein the cyclic moiety is 5- or 6-membered.

22. The compound of claim 19 , wherein n is 1 and L is alkylene.

23. The compound of claim 22 , wherein L is methylene or ethylene.

24. The compound of claim 19 , wherein L is alkylene substituted by aryl, heteroaryl or halo.

25. The compound of claim 1 , wherein the compound of Formula (Ia) is a compound of Formula (IV):

or a pharmaceutically acceptable form thereof, wherein:

W 1 is CR 14 , W 2 is CR 6 , W 3 is CR 7 , W 4 is CR 8 , and W 5 is CR 4 ; and

R 6 , R 7 , R 8 and R 14 are independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, thio, sulfoxide, sulfone, halo, cyano, hydroxy, nitro, phosphate, urea, carbonate, or NR/R″, wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety.

26. The compound of claim 16 , wherein R 8 is hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, sulfonamido, thio, sulfoxide, sulfone, halo, cyano, hydroxy, or NR′R″, wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety.

27. The compound of claim 26 , wherein R 8 is hydrogen or alkyl.

28. The compound of claim 27 , wherein R 8 is alkyl substituted with one or more fluoro.

29. The compound of claim 1 , wherein X is —CH 2 —, —CH(CH 3 )—, —CH(C 6 H 5 )—, or —CH(CH 2 CH 3 )—.

30. The compound of claim 29 , wherein the CH carbon of —CH(CH 3 )— or —CH(CH 2 CH 3 )— has a predominately (S) stereochemical configuration.

31. The compound of claim 1 , wherein Y is absent, —O—, —N(R 9 )—, N(R 9 )C(R 10 ) 2 —, or —S(═O) 2 —.

32. The compound of claim 31 , wherein R 9 and R 10 are independently hydrogen, methyl or ethyl.

33. The compound of claim 1 , wherein X is —(CH(R 10 ) z —, is 1, Y is —N(R 9 )—, and R 9 is hydrogen.

34. The compound of claim 1 , wherein Y is —N(CH 2 CH 3 )CH 2 — or —N(CH 3 )CH 2 —.

35. The compound of claim 1 , wherein X—Y is —CH 2 —N(CH 3 )—, or —CH 2 —N(CH 2 CH 3 )—.

36. The compound of claim 1 , wherein W d is

37. The compound of claim 1 , wherein the compound of Formula (Ia) is a compound of Formula (V):

or a pharmaceutically acceptable form thereof.

38. The compound of claim 37 , or a pharmaceutically acceptable form thereof, wherein:

R 1 is -(L) n -R 1′ ;

each L is —O—, —C(═O)—, —S(═O) 2 —, —S—, or alkylene;

R 1′ is alkyl, hydroxy, aryl, heteroaryl, aralkyl, —(C═O)—NR a1 R a2 , or NR a1 R a2 ;

W d is:

R 10 is hydrogen;

R 12 is hydrogen, halo, haloalkyl, cyano, amino, or amido; and

n is 0, 1, 2, 3, or 4.

39. The compound of claim 38 , wherein L is —O— or alkylene; and n is 0, 1, or 2.

40. A pharmaceutical composition comprising a compound according to claim 1 , and one or more pharmaceutically acceptable excipients.

41. The compound of claim 1 , wherein the compound of Formula (Ia) is:

or a pharmaceutically acceptable form thereof.

42. The pharmaceutical composition of claim 40 , wherein the compound is:

or a pharmaceutically acceptable form thereof.

43. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable form thereof.

44. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable form thereof.

45. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable form thereof.

46. A compound, which is:

or a pharmaceutically acceptable form thereof.

47. The compound of claim 1 , wherein W d is

48. The compound of claim 1 , wherein W d is

49. The compound of claim 1 , wherein W d is

50. The compound of claim 1 , wherein W d is

51. A pharmaceutical composition comprising a compound according to claim 43 , and one or more pharmaceutically acceptable excipients.

52. A pharmaceutical composition comprising a compound according to claim 44 , and one or more pharmaceutically acceptable excipients.

53. A pharmaceutical composition comprising a compound according to claim 45 , and one or more pharmaceutically acceptable excipients.

54. A pharmaceutical composition comprising a compound according to claim 46 , and one or more pharmaceutically acceptable excipients.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2013
From: INTELLIKINE LLC
To: INFINITY PHARMACEUTICALS, INC.
Reel/Frame 030590/0539 →
CHANGE OF NAME Recorded Aug 29, 2012
From: INTELLIKINE, INC.
To: INTELLIKINE LLC
Reel/Frame 028869/0718 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2011
From: REN, PINGDA; LIU, YI; LI, LIANSHENG; CHAN, KATRINA; WILSON, TROY EDWARD
To: INTELLIKINE, INC.
Reel/Frame 027457/0831 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2011
From: CASTRO, ALFREDO C.; EVANS, CATHERINE A.; SNYDER, DANIEL A.
To: INFINITY PHARMACEUTICALS, INC.
Reel/Frame 027457/0858 →
Continuity (3)
Provisional Application 61509454 · Jul 19, 2011
Provisional Application 61412384 · Nov 10, 2010
Related Publication 20120122838A1 · May 17, 2012